HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CLOUDBREAK-B

1.145

-0.010-0.87%

Volume:48.00K

Turnover:55.52K

Market Cap:1.06B

PE:-11.11

High:1.160

Open:1.160

Low:1.145

Close:1.155

52wk High:9.580

52wk Low:0.900

Shares:925.00M

HK Float Shares:925.00M

Volume Ratio:0.54

T/O Rate:0.01%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.103

ROE:--

ROA:-125.66%

PB:2.23

PE(LYR):-11.11

PS:534.08

Loading ...

Overview Company News Filings

Cloudbreak Pharma signs share subscription deal for up to US$15 million with ARC Group unit

CLOUDBREAK-B Issues 5.712 Million Shares Under Equity Incentive Plan

Cloudbreak Pharma - Topline 12-Month Efficacy Data for Cbt-1 Phase 3 Trial Expected in Q3 2026

THOMSON REUTERS

Cloudbreak Pharma Announces Final Patient Visit for 12-Month Efficacy Endpoint in Phase 3 Study of Cbt-001 as a Potential Treatment for Pterygium

THOMSON REUTERS

Cloudbreak-B Completes Final 12-Month Endpoint Visit for CBT-001

Cloudbreak Pharma Submits IND Application For Cbt-358 To FDA

Cloudbreak Pharma Issues AGM Notice; Proposes Director Re-elections, 20% Share Issuance Mandate and 10% Buyback Limit

Bulletin Express

Cloudbreak Pharma Files FDA IND for Dry-Eye Candidate CBT-358

Bulletin Express

Cloudbreak Pharma Revises Allocation of HK$524.60 Million IPO Proceeds, Redirects HK$103.60 Million Toward Expanded R&D and Working Capital

Bulletin Express

CLOUDBREAK-B (02592) Submits Investigational New Drug Application for CBT-358

Cloudbreak Pharma reallocates HK$103.6 million IPO proceeds to expand dry-eye R&D programs

Cloudbreak Pharma submits FDA IND for dry eye drug candidate CBT-358

Cloudbreak Pharma Inc - Submits Ind Application for Cbt-358 to FDA

THOMSON REUTERS

Cloudbreak Pharma Postpones 2026 Annual General Meeting to 26 June

Bulletin Express

Cloudbreak Pharma to present at Stifel Virtual Ophthalmology Forum

CLOUDBREAK-B Receives FDA Clearance for Safety Review of CBT-199

BRIEF-Cloudbreak Pharma Says FDA Completes Safety Review Of CBT-199 IND Application; Clinical Investigation May Proceed

Cloudbreak Pharma Inc - FDA Completes Safety Review of Cbt-199 Ind Application; Clinical Investigation May Proceed

THOMSON REUTERS

Cloudbreak Pharma Completes HK$48.00 Million Fund Redemption, Booking HK$0.88 Million Gain

Bulletin Express

Cloudbreak Pharma Inc - Redeems Fund in Full, Receives HK$48.0 Mln, Records HK$0.88 Mln Gain, 2.53% Annualised Return

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/02592/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02592","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02592\",,,,,undefined,":{"symbol":"02592","market":"HK","secType":"STK","nameCN":"CLOUDBREAK-B","latestPrice":1.145,"timestamp":1788163726631,"preClose":1.155,"halted":0,"volume":48000,"delay":0,"changeRate":-0.008658008658008665,"floatShares":925000000,"shares":925000000,"eps":-0.103023,"marketStatus":"Not Yet Opened","change":-0.01,"latestTime":"08-31 16:08:46","open":1.16,"high":1.16,"low":1.145,"amount":55517,"amplitude":0.012987,"askPrice":1.145,"askSize":6000,"bidPrice":1.14,"bidSize":5000,"shortable":0,"etf":0,"ttmEps":-0.569,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788226200000},"marketStatusCode":0,"adr":0,"listingDate":1751472000000,"exchange":"SEHK","adjPreClose":1.155,"openAndCloseTimeList":[[1788139800000,1788148800000],[1788152400000,1788163200000]],"volumeRatio":0.5405405407231556,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02592\",,,,,undefined,":{"symbol":"02592","floatShares":925000000,"roa":"-125.66%","roe":"--","lyrEps":-0.103023,"volumeRatio":0.5405405407231556,"shares":925000000,"dividePrice":0,"high":1.16,"amplitude":0.012987,"preClose":1.155,"low":1.145,"week52Low":0.9,"pbRate":"2.23","psRate":"534.08","week52High":9.58,"institutionHeld":0,"latestPrice":1.145,"committee":-0.090909,"eps":-0.103023,"divideRate":0,"volume":48000,"delay":0,"ttmEps":-0.569,"open":1.16,"prevYearClose":5.2,"prevWeekClose":1.155,"prevMonthClose":1.145,"prevQuarterClose":1.56,"fiveDayClose":1.18,"twentyDayClose":1.165,"sixtyDayClose":1.18},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02592\",params:#limit:5,,,undefined,":[{"date":"2026-08-31","symbol":"02592","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1788139800000,"name":null,"time":"","dateTimestamp":1788105600000,"actualEps":null},{"date":"2026-03-30","symbol":"02592","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774834200000,"name":null,"time":"","dateTimestamp":1774800000000,"actualEps":null},{"date":"2025-08-29","symbol":"02592","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02592\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02592\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02592\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02592","date":"2026-08-28","current":-2.012302,"percent":0.978873,"low":-24.505522,"twenty":-11.868929,"median":-5.708624,"eighty":-2.114609,"high":-1.560159,"avg":-6.72204,"sd":4.923992,"marketCap":975473605},"quantilePoints":[{"date":"2025-07-04","current":-6.317277,"twenty":-6.610502,"median":-6.500542,"eighty":-6.390583,"marketCap":4915912241},{"date":"2025-07-11","current":-6.166376,"twenty":-6.470405,"median":-6.317277,"eighty":-6.263403,"marketCap":4798467239},{"date":"2025-07-18","current":-6.350904,"twenty":-6.498689,"median":-6.350281,"eighty":-6.263403,"marketCap":4941079027},{"date":"2025-07-25","current":-6.080141,"twenty":-6.48004,"median":-6.306537,"eighty":-6.134066,"marketCap":4731355809},{"date":"2025-08-01","current":-5.497985,"twenty":-6.418895,"median":-6.177156,"eighty":-6.011186,"marketCap":4278353657},{"date":"2025-08-08","current":-5.49809,"twenty":-6.350655,"median":-6.13405,"eighty":-5.65539,"marketCap":4278353657},{"date":"2025-08-15","current":-5.725306,"twenty":-6.343182,"median":-6.058573,"eighty":-5.554248,"marketCap":4446132232},{"date":"2025-08-22","current":-5.53457,"twenty":-6.315129,"median":-6.004685,"eighty":-5.554248,"marketCap":4286742586},{"date":"2025-08-29","current":-5.503941,"twenty":-6.295753,"median":-5.870846,"eighty":-5.538055,"marketCap":4253186871},{"date":"2025-09-05","current":-5.413205,"twenty":-6.239682,"median":-5.742284,"eighty":-5.49926,"marketCap":4186075441},{"date":"2025-09-12","current":-12.640894,"twenty":-6.350655,"median":-5.870846,"eighty":-5.508123,"marketCap":4118964011},{"date":"2025-09-19","current":-12.711577,"twenty":-6.612702,"median":-6.004685,"eighty":-5.525012,"marketCap":4135741868},{"date":"2025-09-26","current":-11.804503,"twenty":-12.358821,"median":-6.058573,"eighty":-5.527436,"marketCap":3842129362},{"date":"2025-10-03","current":-6.439136,"twenty":-12.191113,"median":-6.134046,"eighty":-5.53457,"marketCap":2096453591},{"date":"2025-10-10","current":-5.988337,"twenty":-11.881825,"median":-6.134089,"eighty":-5.548508,"marketCap":1949083838},{"date":"2025-10-17","current":-12.3346,"twenty":-12.21981,"median":-6.187936,"eighty":-5.561014,"marketCap":4009907937},{"date":"2025-10-24","current":-11.844495,"twenty":-12.25273,"median":-6.279578,"eighty":-5.580054,"marketCap":3850518291},{"date":"2025-10-31","current":-12.15705,"twenty":-12.335851,"median":-6.333467,"eighty":-5.585568,"marketCap":3951185436},{"date":"2025-11-07","current":-11.838569,"twenty":-12.273198,"median":-6.424535,"eighty":-5.601607,"marketCap":3850518291},{"date":"2025-11-14","current":-11.510378,"twenty":-12.207573,"median":-6.465107,"eighty":-5.621104,"marketCap":3741462218},{"date":"2025-11-21","current":-12.23865,"twenty":-12.234818,"median":-6.500592,"eighty":-5.630174,"marketCap":3984741151},{"date":"2025-11-28","current":-21.343443,"twenty":-12.412307,"median":-6.613869,"eighty":-5.677994,"marketCap":6946032996},{"date":"2025-12-05","current":-20.614529,"twenty":-12.626633,"median":-6.790202,"eighty":-5.718633,"marketCap":6711142992},{"date":"2025-12-12","current":-17.961539,"twenty":-12.716498,"median":-11.142834,"eighty":-5.735493,"marketCap":5847083331},{"date":"2025-12-19","current":-14.819321,"twenty":-12.837409,"median":-11.27102,"eighty":-5.75741,"marketCap":4823634025},{"date":"2025-12-24","current":-14.055026,"twenty":-12.984934,"median":-11.600706,"eighty":-5.767869,"marketCap":4571966163},{"date":"2026-01-02","current":-11.620216,"twenty":-12.995771,"median":-11.729724,"eighty":-5.769371,"marketCap":3783406861},{"date":"2026-01-09","current":-7.540769,"twenty":-12.961935,"median":-11.510378,"eighty":-5.972321,"marketCap":2457956120},{"date":"2026-01-16","current":-8.049692,"twenty":-12.941587,"median":-11.169175,"eighty":-5.988337,"marketCap":2625734695},{"date":"2026-01-23","current":-6.609576,"twenty":-12.863288,"median":-10.620058,"eighty":-5.996682,"marketCap":2155954686},{"date":"2026-01-30","current":-6.294491,"twenty":-12.820156,"median":-9.452561,"eighty":-6.004685,"marketCap":2055287541},{"date":"2026-02-06","current":-5.800172,"twenty":-12.797534,"median":-8.075865,"eighty":-6.004685,"marketCap":1895897895},{"date":"2026-02-13","current":-5.772062,"twenty":-12.788929,"median":-7.957902,"eighty":-5.976779,"marketCap":1887508966},{"date":"2026-02-20","current":-5.722622,"twenty":-12.762909,"median":-7.89408,"eighty":-5.899654,"marketCap":1870731109},{"date":"2026-02-27","current":-5.716309,"twenty":-12.718958,"median":-7.540769,"eighty":-5.819712,"marketCap":1870731109},{"date":"2026-03-06","current":-5.592845,"twenty":-12.7039,"median":-6.802294,"eighty":-5.77076,"marketCap":1828786465},{"date":"2026-03-13","current":-5.252211,"twenty":-12.674344,"median":-6.763399,"eighty":-5.752368,"marketCap":1719730391},{"date":"2026-03-20","current":-4.787506,"twenty":-12.644727,"median":-6.625153,"eighty":-5.711698,"marketCap":1568729674},{"date":"2026-03-27","current":-4.279308,"twenty":-12.631386,"median":-6.530805,"eighty":-5.600393,"marketCap":1400951099},{"date":"2026-04-02","current":-4.3756,"twenty":-12.611231,"median":-6.512878,"eighty":-5.567465,"marketCap":1434506814},{"date":"2026-04-10","current":-4.248889,"twenty":-12.593551,"median":-6.499576,"eighty":-5.532786,"marketCap":1392562170},{"date":"2026-04-17","current":-3.434267,"twenty":-12.529717,"median":-6.439136,"eighty":-5.502771,"marketCap":1124116451},{"date":"2026-04-24","current":-3.028108,"twenty":-12.499065,"median":-6.412742,"eighty":-5.465751,"marketCap":1604675194},{"date":"2026-04-30","current":-2.35827,"twenty":-12.455796,"median":-6.350281,"eighty":-5.436669,"marketCap":1249957520},{"date":"2026-05-08","current":-2.422963,"twenty":-12.412307,"median":-6.306537,"eighty":-5.348441,"marketCap":1283740155},{"date":"2026-05-15","current":-2.215232,"twenty":-12.362936,"median":-6.237324,"eighty":-5.224545,"marketCap":1173946589},{"date":"2026-05-22","current":-2.103037,"twenty":-12.335851,"median":-6.187936,"eighty":-5.079251,"marketCap":1114826977},{"date":"2026-05-29","current":-2.055189,"twenty":-12.29622,"median":-6.159956,"eighty":-4.693687,"marketCap":1089490000},{"date":"2026-06-05","current":-1.943602,"twenty":-12.236095,"median":-6.134636,"eighty":-4.452767,"marketCap":1030370388},{"date":"2026-06-12","current":-2.070618,"twenty":-12.215803,"median":-6.134042,"eighty":-4.302022,"marketCap":1097935659},{"date":"2026-06-18","current":-1.863414,"twenty":-12.1843,"median":-6.080141,"eighty":-4.208883,"marketCap":988142093},{"date":"2026-06-26","current":-1.607919,"twenty":-12.150518,"median":-6.004708,"eighty":-3.379693,"marketCap":853011550},{"date":"2026-07-03","current":-2.053171,"twenty":-12.124388,"median":-5.992509,"eighty":-2.739542,"marketCap":1089490000},{"date":"2026-07-10","current":-2.134398,"twenty":-12.109822,"median":-5.972321,"eighty":-2.532616,"marketCap":1131718295},{"date":"2026-07-17","current":-2.101828,"twenty":-11.973906,"median":-5.886479,"eighty":-2.422963,"marketCap":1114826977},{"date":"2026-07-24","current":-2.069578,"twenty":-11.968515,"median":-5.84391,"eighty":-2.309668,"marketCap":1097935659},{"date":"2026-07-31","current":-1.862057,"twenty":-11.947093,"median":-5.798666,"eighty":-2.247923,"marketCap":988142093},{"date":"2026-08-07","current":-1.925288,"twenty":-11.910048,"median":-5.770977,"eighty":-2.212119,"marketCap":1021924729},{"date":"2026-08-14","current":-1.869116,"twenty":-11.882099,"median":-5.767494,"eighty":-2.165101,"marketCap":992364923},{"date":"2026-08-21","current":-1.909914,"twenty":-11.871403,"median":-5.723964,"eighty":-2.134253,"marketCap":1013479070},{"date":"2026-08-28","current":-1.839188,"twenty":-11.868929,"median":-5.708624,"eighty":-2.114609,"marketCap":975473605}],"updateTime":1788182470283},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02592\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2644084210","title":"Cloudbreak Pharma signs share subscription deal for up to US$15 million with ARC Group unit","url":"https://stock-news.laohu8.com/highlight/detail?id=2644084210","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644084210?lang=en_us&edition=fundamental","pubTime":"2026-06-18 22:51","pubTimestamp":1781794269,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma entered a share subscription deal for up to USD 15 million of new shares with ARC Group International.Issuance can occur in multiple drawdowns over 12 months, capped at 167,778,574 shares under an existing general mandate.Pricing set at 93% of average closing bid over a 15-day pricing period, subject to a floor of HKD 1.03.Maximum net proceeds estimated at USD 14.51 million, earmarked for R&D, PRC bank loan repayment, working capital.Commitment fee set at USD 0.3 million in cash, with 60% payable within five business days.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cloudbreak Pharma Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong K","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDL3Ch96D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113708786","title":"CLOUDBREAK-B Issues 5.712 Million Shares Under Equity Incentive Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1113708786","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113708786?lang=en_us&edition=fundamental","pubTime":"2026-06-09 16:38","pubTimestamp":1780994299,"startTime":"0","endTime":"0","summary":"CLOUDBREAK-B (02592) has announced the allotment and issuance of 5.712 million shares.The issuance was completed on June 9, 2026, in accordance with the company's 2023 equity incentive plan.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641453167","title":"Cloudbreak Pharma - Topline 12-Month Efficacy Data for Cbt-1 Phase 3 Trial Expected in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2641453167","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641453167?lang=en_us&edition=fundamental","pubTime":"2026-06-05 05:00","pubTimestamp":1780606800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nTUA73ZCCQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641167454","title":"Cloudbreak Pharma Announces Final Patient Visit for 12-Month Efficacy Endpoint in Phase 3 Study of Cbt-001 as a Potential Treatment for Pterygium","url":"https://stock-news.laohu8.com/highlight/detail?id=2641167454","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641167454?lang=en_us&edition=fundamental","pubTime":"2026-06-05 05:00","pubTimestamp":1780606800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nTUA73ZCCQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112548739","title":"Cloudbreak-B Completes Final 12-Month Endpoint Visit for CBT-001","url":"https://stock-news.laohu8.com/highlight/detail?id=1112548739","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112548739?lang=en_us&edition=fundamental","pubTime":"2026-06-04 18:52","pubTimestamp":1780570358,"startTime":"0","endTime":"0","summary":"The final patient has completed a 12-month visit, during which the primary efficacy endpoints of CBT-001—the degree of pterygium lesion reduction and ocular discomfort symptom scores—were evaluated...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBT","BK1161","BK4090","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637343690","title":"Cloudbreak Pharma Submits IND Application For Cbt-358 To FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2637343690","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637343690?lang=en_us&edition=fundamental","pubTime":"2026-05-22 23:26","pubTimestamp":1779463570,"startTime":"0","endTime":"0","summary":"May 22 (Reuters) - Cloudbreak Pharma Inc <2592.HK>::*SUBMITS IND APPLICATION FOR CBT-358 TO FDA*Further company coverage: 2592.HK* ((Reuters.Briefs@thomsonreuters.com;))  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 22-MAY-202615:07:00.113 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nRSD9hDhvr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117476828","title":"Cloudbreak Pharma Issues AGM Notice; Proposes Director Re-elections, 20% Share Issuance Mandate and 10% Buyback Limit","url":"https://stock-news.laohu8.com/highlight/detail?id=1117476828","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117476828?lang=en_us&edition=fundamental","pubTime":"2026-05-22 23:23","pubTimestamp":1779463411,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma Inc. (CLOUDBREAK-B) has released its notice of Annual General Meeting, scheduling the session for 26 June 2026 at 09:30 a.m. Hong Kong Time (25 June 2026 at 06:30 p.m. PDT) at 8921...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196922661","title":"Cloudbreak Pharma Files FDA IND for Dry-Eye Candidate CBT-358","url":"https://stock-news.laohu8.com/highlight/detail?id=1196922661","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196922661?lang=en_us&edition=fundamental","pubTime":"2026-05-22 22:43","pubTimestamp":1779461021,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma Inc. (Cloudbreak) has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration on 21 May 2026 for CBT-358, according to a voluntary...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120533332","title":"Cloudbreak Pharma Revises Allocation of HK$524.60 Million IPO Proceeds, Redirects HK$103.60 Million Toward Expanded R&D and Working Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=1120533332","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120533332?lang=en_us&edition=fundamental","pubTime":"2026-05-22 22:43","pubTimestamp":1779460989,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma Inc. announced a material re-allocation of the HK$524.60 million net proceeds raised in its June 2025 global offering, shifting HK$103.60 million from the originally earmarked Phase...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100019197","title":"CLOUDBREAK-B (02592) Submits Investigational New Drug Application for CBT-358","url":"https://stock-news.laohu8.com/highlight/detail?id=1100019197","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100019197?lang=en_us&edition=fundamental","pubTime":"2026-05-22 22:40","pubTimestamp":1779460828,"startTime":"0","endTime":"0","summary":"CLOUDBREAK-B (02592) announced that on May 21, 2026, the group submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for CBT-358. CBT-358 is the most...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","CBT","02592","BK4090"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637348801","title":"Cloudbreak Pharma reallocates HK$103.6 million IPO proceeds to expand dry-eye R&D programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2637348801","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637348801?lang=en_us&edition=fundamental","pubTime":"2026-05-22 22:37","pubTimestamp":1779460672,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma outlined a revised funding plan for the HK$524.6 million in net IPO proceeds, shifting HK$103.6 million away from CBT-009 following the decision to withdraw its current China IND application for a possible phase 3 trial.Reallocated funds target faster clinical and regulatory work on CBT-001 and CBT-004, accelerated development of SFA+ pipeline assets including CBT-358 and CBT-277, and higher general corporate funding.Under the revised plan, total allocations rise to HK$359.2 million for CBT-001 and CBT-004 programs, HK$84.1 million for CBT-009, CBT-358 and CBT-277, HK$28.8 million for manufacturing and commercialization, and HK$52.5 million for working capital.Unutilized proceeds stood at HK$312.6 million, with spending to be governed by tighter board-level budgeting and authorization controls.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDL7HxKHn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637310073","title":"Cloudbreak Pharma submits FDA IND for dry eye drug candidate CBT-358","url":"https://stock-news.laohu8.com/highlight/detail?id=2637310073","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637310073?lang=en_us&edition=fundamental","pubTime":"2026-05-22 22:33","pubTimestamp":1779460438,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma submitted a US FDA investigational new drug application for CBT-358 on May 21, 2026.The filing starts the FDA review needed to clear the candidate into clinical trials for dry eye disease.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cloudbreak Pharma Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on May 22, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDL1f1jVW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637310026","title":"Cloudbreak Pharma Inc - Submits Ind Application for Cbt-358 to FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2637310026","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637310026?lang=en_us&edition=fundamental","pubTime":"2026-05-22 22:33","pubTimestamp":1779460436,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nFWN41Z0NN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143070511","title":"Cloudbreak Pharma Postpones 2026 Annual General Meeting to 26 June","url":"https://stock-news.laohu8.com/highlight/detail?id=1143070511","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143070511?lang=en_us&edition=fundamental","pubTime":"2026-05-20 16:43","pubTimestamp":1779266633,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma Inc. (HKEX: 02592, “Cloudbreak-B”) has rescheduled its forthcoming Annual General Meeting, originally set for 29 May 2026, to 26 June 2026. The Board cited the need for additional...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634038216","title":"Cloudbreak Pharma to present at Stifel Virtual Ophthalmology Forum","url":"https://stock-news.laohu8.com/highlight/detail?id=2634038216","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634038216?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:02","pubTimestamp":1778587333,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma will participate in Stifel 2026 Virtual Ophthalmology Forum on May 26, 2026.Virtual fireside chat scheduled for 4:00 p.m. ET.Virtual one-on-one meetings with institutional investors planned throughout day.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDLbnX8kN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","SF","IE00B3QW5Z07.USD","BK4112","SG9999014039.USD","BK4585","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2095319765.USD","BK4588","IE00BN0W2W23.USD","SG9999014013.SGD","SG9999014005.SGD","NDAQ","IE00BN0W2V16.EUR","LU2210149790.SGD","LU2210150020.SGD","IE00BN0W2T93.GBP","SG9999014021.USD","BK4127","02592","IE00B64PRP62.GBP","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105385618","title":"CLOUDBREAK-B Receives FDA Clearance for Safety Review of CBT-199","url":"https://stock-news.laohu8.com/highlight/detail?id=1105385618","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105385618?lang=en_us&edition=fundamental","pubTime":"2026-04-30 16:50","pubTimestamp":1777539018,"startTime":"0","endTime":"0","summary":"CLOUDBREAK-B (02592) announced that its wholly-owned subsidiary, ADS Therapeutics LLC, incorporated in Delaware, USA, has completed the review period for the Investigational New Drug (IND)...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4090","BK1161","CBT","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631865376","title":"BRIEF-Cloudbreak Pharma Says FDA Completes Safety Review Of CBT-199 IND Application; Clinical Investigation May Proceed","url":"https://stock-news.laohu8.com/highlight/detail?id=2631865376","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631865376?lang=en_us&edition=fundamental","pubTime":"2026-04-30 16:39","pubTimestamp":1777538344,"startTime":"0","endTime":"0","summary":"BRIEF-Cloudbreak Pharma Says FDA Completes Safety Review Of CBT-199 IND Application; Clinical Investigation May ProceedApril 30  - Cloudbreak Pharma Inc 2592.HK:FDA COMPLETES SAFETY REVIEW OF CBT-199 IND APPLICATION; CLINICAL INVESTIGATION MAY PROCEEDFurther company coverage: 2592.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nFWN41D0P6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631668639","title":"Cloudbreak Pharma Inc - FDA Completes Safety Review of Cbt-199 Ind Application; Clinical Investigation May Proceed","url":"https://stock-news.laohu8.com/highlight/detail?id=2631668639","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631668639?lang=en_us&edition=fundamental","pubTime":"2026-04-30 16:37","pubTimestamp":1777538249,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nFWN41D0P6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136105724","title":"Cloudbreak Pharma Completes HK$48.00 Million Fund Redemption, Booking HK$0.88 Million Gain","url":"https://stock-news.laohu8.com/highlight/detail?id=1136105724","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136105724?lang=en_us&edition=fundamental","pubTime":"2026-04-22 21:03","pubTimestamp":1776862995,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma Inc. (CLOUDBREAK-B) has fully redeemed its investment in an offshore fund, receiving HK$48.00 million in proceeds and realizing a HK$0.88 million gain, equivalent to an annualised...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629049285","title":"Cloudbreak Pharma Inc - Redeems Fund in Full, Receives HK$48.0 Mln, Records HK$0.88 Mln Gain, 2.53% Annualised Return","url":"https://stock-news.laohu8.com/highlight/detail?id=2629049285","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629049285?lang=en_us&edition=fundamental","pubTime":"2026-04-22 20:42","pubTimestamp":1776861766,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nFWN415089:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":61,"code":"91000000","status":"200"}]}}